Učitavanje...
4CPS-133 Response to vemurafenib-cobimetinib with reduced doses in a patient with metastasic melanoma: concerning a case
BACKGROUND: Melanoma is the cutaneous tumour with the highest mortality. BRAF inhibitors are indicated for patients with metastatic melanoma and are part of the first-line treatment of this disease. PURPOSE: To describe the clinical course of a patient diagnosed with metastatic melanoma who develope...
Spremljeno u:
| Izdano u: | Eur J Hosp Pharm |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Group
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535375/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.224 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|